Wel-Bloom Biotech Launches Wel-ROS6. Black Crystal Roselle Sparks a Surge in High-Concentration Anthocyanins
--> Black Crystal Roselle Shakes Up the Anthocyanin Market with 17.7x Natural Concentration
--> Taiwan's Black Crystal Roselle Emerges as a Key Player in the Anthocyanin and Health Markets
--> Anthocyanin Levels Surge in Black Crystal Roselle — Spotlight on Key Ingredient Wel-ROS6
--> Wel-ROS6 in Black Crystal Roselle Raises the Bar for Health Supplements
TAIPEI, TAIWAN - Media OutReach Newswire - 22 July 2025 - Taiwan's leading jelly supplement manufacturer, Wel-Bloom Biotech, recently co-hosted an anthocyanin-focused seminar with LEARN EATiNG, one of the most renowned nutritionist teams in Taiwan. The event highlighted trending international ingredients alongside Taiwan's own Black Crystal Roselle. Attracting around 300 nutrition professionals both online and onsite, the seminar reflected strong industry interest and high expectations for the future of anthocyanin innovation.
In recent years, the health supplement market has seen rapid growth, accompanied by a shift in consumer priorities. Today's consumers increasingly believe that 'choosing the right ingredients matters more than simply taking more,' a mindset that is driving innovation in ingredient formulation. According to the 2024 Top 30 Dietary Trends Report, there is growing interest in the synergistic effects of ingredient combinations. For instance, pairing anthocyanins with fish oil offers comprehensive support for overall health, while combining them with collagen enhances beauty and skin wellness.
The Black Crystal Roselle, grown locally in Taiwan, contains naturally high levels of anthocyanins and has recently drawn growing interest in the health supplement field for its promising nutritional potential.
As one of the keynote speakers, Wel-Bloom Biotech introduced Wel-ROS6®—a proprietary botanical ingredient derived from Black Crystal Roselle. Developed using triple-patented technology, it is cultivated through natural farming methods and smallholder contract farming to ensure consistent quality and traceability. Laboratory data shows that Wel-ROS6® contains 17.7 times more total anthocyanins than standard commercial roselle. Additionally, total phenolic acids and flavonoids are elevated by 1.9 times and 1.3 times, respectively—highlighting its rich phytochemical profile and high functional value. (See Note 1)
The event also featured the Food Industry Research and Development Institute's newly proposed 'Food Value Equation':
Value = (Sensory Perception × Functional Technology × User Experience) × Amplification Multiplier.
This formula highlights the importance of balancing sensory appeal, technological innovation, and user experience—emphasizing that all three elements are essential to creating meaningful value in food products.
To meet growing consumer demands for convenience and palatability in health supplements, product development is increasingly focused on factors such as absorption efficiency, flavor optimization, and sustainable sourcing. The rise of 'tasty' health products reflects a major trend in preventive wellness—perfectly aligned with today's mindset of 'eating less, supplementing smarter.' Through its one-stop CDMO (Contract Development and Manufacturing Organization) services, Taiwan's local agriculture can now be transformed from raw materials into globally market-ready products that seamlessly integrate into everyday life.
Wel-ROS6®, backed by the support of over 300 health professionals, will be featured alongside other cutting-edge botanical ingredients at the 2025 BIO Asia–Taiwan Exhibition and Vitafoods Asia.
We warmly invite you to visit our booth and explore partnership opportunities with Wel-Bloom Biotech to co-create the next generation of best-selling health supplements.
Note 1:
Testing commissioned to the Food Industry Research and Development Institute:
--> Total phenolic content: Measured using the Folin–Ciocalteu colorimetric assay.
--> Total flavonoid content: Measured using the AlCl₃–NaNO₂–NaOH colorimetric method (also known as the Aluminum chloride colorimetric assay).
Independent testing by the Forecast Research Lab:
--> Anthocyanins (Delphinidin chloride, Cyanidin chloride): Quantified using HPLC analysis
--> Total anthocyanins: Measured by the pH differential method
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
2 hours ago
- Barnama
ExP Realty Launches In Japan, Marking Fourth Global Market Entry In 2025
BELLINGHAM, Wash., July 28 (Bernama) -- eXp Realty®, the largest independent real estate brokerage in the world and a core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced its official expansion into Japan, marking the company's fourth international launch of the year, following Peru, Türkiye, and Ecuador. "Agents in Japan have operated for years in a system that leaves little room for upside,' said Felix Bravo, Managing Director, International at eXp Realty. 'It's not about working harder, they already do. The problem is structural. Most models take too much and give too little in return. We're bringing a platform that flips that equation. Better economics, real ownership, worldwide leverage. That's what eXp is about.'
The Sun
2 days ago
- The Sun
VinFast Indonesia to expand dealership network to 85 showrooms nationwide
JAKARTA, INDONESIA - Media OutReach Newswire - 26 July 2025 - VinFast, the Vietnamese Nasdaq-listed EV manufacturer, has officially signed agreements with 20 new dealership partners during the Gaikindo Indonesia International Auto Show (GIIAS) 2025. These agreements will bring VinFast closer to its goal of operating 100 dealership showrooms this year. This marks a strategic advancement for VinFast in its journey to conquer the Indonesian market, and underscores its commitment to delivering superior products and services to consumers across the archipelago. The 20 new VinFast dealership partners are highly reputable and capable enterprises in Indonesia's automotive sector. They include PT Auto Green AAS, PT Ivan Dijaja Mandiri, PT Bimmeroom Mobil Indonesia, PT Alto Anugerah Abadi, PT Prestisius Indonesia, and PT Mega Central Autoniaga, etc. Each partner was meticulously selected based on their strong market position and extensive experience in strategic regions. According to the signed dealer agreements and Memoranda of Understanding, the 20 new dealerships are expected to operate a total of 38 VinFast showrooms, which will progressively become operational from the time of signing until the end of 2026. Meanwhile, existing dealerships will open an additional 23 showrooms, bringing the total number of dealerships in VinFast's retail network in Indonesia to 34 dealerships and expected 85 showrooms. The strategic collaboration with these trusted partners is expected to significantly accelerate VinFast's expansion, swiftly establishing a comprehensive distribution and service network across Indonesia's key regions, expanding VinFast's presence to 19 provinces and 41 cities in Indonesia. This move aims to ensure VinFast's smart EVs are readily accessible to a broad spectrum of Indonesian consumers, while simultaneously reinforcing an international-standard after-sales service system in pivotal population centers. Throughout the entire cooperation process, VinFast is committed to providing maximum support to its authorized dealers. This includes implementing comprehensive and continuous training programs for dealership personnel, equipping them with solid professional knowledge about products, technology, and maintenance and repair procedures in accordance with VinFast's global standards. Mr. Ivan Farrel Djayaprawira, Director of PT Ivan Djaja Mandiri, stated: 'As a strategic partner of VinFast, we are proud to contribute modern infrastructure, superior capabilities, established reputation, and deep understanding of the Indonesian market. Joining VinFast in its journey to accelerate the global green revolution, we have strong confidence in the explosive potential of electric vehicles and VinFast's prospects here. We are committed to creating optimal value for a mutually beneficial partnership, thereby delivering top-quality electric vehicle products and services that best meet customer needs.' Mr. Kariyanto Hardjosoemarto, CEO of VinFast Indonesia, shared: 'With VinFast's comprehensive support for our dealership partners, we are committed to ensuring that every customer in Indonesia will always experience professional consulting services and outstanding after-sales policies, providing absolute peace of mind when purchasing and owning a vehicle. In the spirit of this strong cooperation, VinFast and our dealership network will unite to work towards the goal of creating a green mobility future for Indonesia, actively contributing to the nation's EV development roadmap and delivering practical, meaningful value to society.' VinFast is accelerating its retail network expansion amidst a continuously growing range of products in the Indonesian market. In just over a year since officially entering the market, VinFast has swiftly introduced a diverse product lineup covering the most popular segments, from the VF 3, VF 5, VF 6 to the VF e34, and most recently, the VF 7. These products are all offered with exceptionally attractive sales and after-sales policies, such as complimentary charging at V-GREEN charging stations and 0% interest financing support for vehicle purchases. Simultaneously, VinFast continues to foster partnerships with after-sales service providers, workshops, and banks, maximizing convenience for Indonesian consumers transitioning to green mobility.
Malaysian Reserve
2 days ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
